Combined detection of p504s、34βE12 expression in prostate cancer and its clinical significance

Objective To evaluate the expression and clinical application of p504s and 34βE12 in benign and malignant prostate lesions.Methods Immunohistochemical labeled dextran polymer (LDP) method was used to detect the expression of p504s and 34βE12 in benign and malignant prostate lesions.Results The positive expression rate of p504s in the 49 cases of Prostate Cancer (Pca) tissues was 93.88% (46/49).No expression of 34βE12 was detected.The positive expression rate of 34βE12 was detected in the 30 cases (30/30) of benign prostatic hyperplasia (BPH).No expression of p504s was in BPH.There was significant difference (P 0.05) between the 2 proteins' positive expression in Pca and BPH tissues.The expression of p504s was positively correlated to tumor pathological grades (P 0.05) and tumor clinical stages (P 0.05).Conclusions p504s is a sensitive and specific prostate cancer (Pca) marker.Combined detection of p504s and 34βE12 can greatly improve the diagnosis of prostatic cancer.